Perhaps, a cytopheretic method could be added to the armamentarium of SCD therapies that removes CD11b+ SCD monocytes that produce TNF-a and/or IL-1b in patients who fail to respond to first- or second-line treatment. This evidence concerns the gene IL1B and Schnyder corneal dystrophy.